Stomach cancer (credit: canva)
Stomach cancer is a type of cancer that develops in the lining of the stomach. Also, known as Gastric cancer, it affects the elderly more than the adult. According to the American Cancer Society, about 6 of every 10 people diagnosed with stomach cancer each year are 65 or older. Also, the lifetime risk of developing stomach cancer is higher in men (about 1 in 101) than in women (about 1 in 155).
A health expert, speaking to a leading media house, emphasized five common symptoms of stomach cancer that should not be ignored:
1. Unexplained weight loss: Losing weight without trying or experiencing an unexplained drop in appetite, which may signal cancer progression.
2. Pain in the upper part of the abdomen: Persistent or occasional pain in the stomach area, often after eating, can become more severe as the condition progresses.
3. Frequent vomiting after meals: Nausea, sometimes accompanied by vomiting, may occur especially after meals and is linked to cancer blocking or irritating the stomach.
4. Vomiting blood, which may appear coffee-colored: This can indicate bleeding in the stomach, often caused by ulcers or tumors, and requires immediate medical attention.
5. Black, tarry stools: This occurs when blood from the stomach is digested and passed through the intestines, signaling potential internal bleeding
There are also other concerning signs that should not be overlooked such as jaundice, unexplained weight loss, early onset of diabetes, dark stools, and loss of appetite. Health experts strongly advise seeking immediate medical attention if you notice any of these symptoms. If you or a loved one experience these signs, it's crucial to visit a physician for a thorough evaluation to rule out serious underlying health conditions.
Oncologist Dr Pankaj Kumar Pande, Director–Surgical Oncology, Max Super Specialty Hospital, Shalimar Bagh, Delhi explained that this form of cancer spreads through three main pathways: Direct spread, lymphatic spread, and bloodstream.
1. Direct Spread: In its early stages, stomach cancer can invade nearby tissues and grow into the deeper layers of the stomach or spread to surrounding organs such as the oesophagus, liver, pancreas, or intestines.
2. Lymphatic Spread: Cancer cells can travel through the lymphatic system. The most common areas affected are the regional lymph nodes near the stomach, particularly those around the liver and diaphragm.
3. Bloodstream: "Cancer cells can enter the bloodstream and travel to distant parts of the body," which is a common route for stomach cancer to metastasize to distant organs.
He further explained that cancerous cells spread from the original tumour to other parts of the body through a process called Metastasis. The most common sites for the spread are the liver, lymph nodes, peritoneum, lungs, bones, and ovaries.
Credit: AI image
In a first for India, Maharashtra has allowed qualified homeopathy practitioners to prescribe certain modern medicines after completing a one-year Certificate Course in Modern Pharmacology (CCMP).
The decision has sparked strong opposition from the Indian Medical Association (IMA) and several doctors' bodies, which have announced protests, citing concerns over patient safety, medical education, and professional standards.
Under a Government Resolution (GR) issued on August 3, Maharashtra has allowed BHMS graduates who have completed the one-year Certificate Course in Modern Pharmacology (CCMP) to register with the Maharashtra Medical Council (MMC). The registration allows eligible practitioners to prescribe specified modern medicines under the state's policy.
The MMC began registering CCMP-qualified practitioners on August 5. According to reports, one practitioner has been registered so far, while around 2,500 applications remain pending.
The IMA has warned of a nationwide strike if the Maharashtra government does not withdraw its decision. In a letter to Maharashtra Chief Minister Devendra Fadnavis, signed by IMA National President Dr. Anilkumar J. Nayak and Secretary General Dr. Sarbari Dutta, the association demanded immediate withdrawal of both the GR and the CCMP course.
The IMA has raised the following concerns:
The Certificate Course in Modern Pharmacology (CCMP) is a one-year program introduced in Maharashtra in 2016 by the Maharashtra University of Health Sciences (MUHS). It is designed for BHMS (Bachelor of Homeopathic Medicine and Surgery) graduates and trains them in aspects of modern pharmacology and allopathic medicine.
The CCMP course was introduced following a major agitation by homeopathic associations, including a 13-day indefinite hunger strike in Nagpur in 2013, demanding legal rights to prescribe essential modern medicines.
According to the Maharashtra government, the objective was to strengthen healthcare delivery, particularly in areas facing shortages of doctors.
To facilitate the course, the state amended the Maharashtra Homoeopathy Practitioners' Act, 1960 and the Maharashtra Medical Council Act, 1965 in 2014, after the legislation was passed by both Houses of the State Legislature.
The IMA now argued that the situation in 2014 when the MMC Act was amended is very different from the situation now.
The medical body cited the cancellation of "bond system for MBBS graduates due to the nonavailability of vacant posts for them even in rural areas- signifying sufficient availability of MBBS doctors".
According to the government, the one-year CCMP curriculum was developed by expert committees at MUHS after comparing the BHMS and MBBS syllabi to bridge gaps in training.
The course includes:
The government says the program is intended to make registered homeopathic practitioners competent to prescribe specified modern medicines and improve access to healthcare in the state.
But the IMA has argued that such "short-term certification or bridge courses cannot substitute for comprehensive medical education". They also warned that permitting cross-practice would compromise patient safety.
The Maharashtra Association of Resident Doctors (MARD) began an indefinite statewide strike on August 3. On August 5, doctors across Mumbai withdrew routine outpatient department (OPD) services in protest against the government's decision.
Doctors from Pune are scheduled to join their counterparts in Mumbai for demonstrations at Azad Maidan on August 6. The IMA has warned of a nationwide strike if the Maharashtra government does not withdraw the decision. The IMA Kerala State Branch has also extended support to the Maharashtra doctors' protest.
Credit: iStock
A severe COVID-19 infection may awaken dormant viruses that remain hidden in the body for life, even in people with otherwise healthy immune systems, according to a study published in Nature.
The study, which analyzed more than 1,100 hospitalized COVID-19 patients, found that viral reactivation was common and may contribute to long COVID symptoms. Researchers said the findings suggest COVID-19 can disrupt the body's internal ecosystem of dormant viruses, creating a state they describe as "dysvirosis."
"This finding suggests that COVID-19 may not always act as a single viral infection and may disrupt the body's internal ecosystem of dormant viruses, creating a state of 'dysvirosis'," said lead author Cole Maguire from Dell Medical School at The University of Texas at Austin.
Nearly half of the hospitalized patients had at least one dormant virus reactivate during their COVID-19 illness. The viruses identified included:
Also read: Lab Leak 'More Likely' Origin of COVID-19, Says Former Biden Adviser Dr. Ashish Jha
The researchers found that viral reactivation was more common in patients with severe COVID-19 and those who had longer hospital stays, and caused:
The study also noted that these viruses have previously been linked to autoimmune conditions such as multiple sclerosis and lupus.
Further, the study found that dormant viruses do not reactivate simultaneously after SARS-CoV-2 infection.
Earlier research had mainly observed viral reactivation in people with weakened immune systems. However, this study found that reactivation frequently occurred in people who were healthy before developing COVID-19.
According to the researchers, this suggests viral reactivation may be more common than previously believed and could contribute to worse outcomes even in otherwise healthy individuals.
Read More: Can Long COVID Be Prevented Before It Starts? Study Suggests Early Paxlovid May Help
While the study does not prove that viral reactivation causes long COVID, it provides strong evidence that dormant viruses may contribute to the condition.
Researchers found that Anelloviridae appeared more frequently in patients with long COVID who experienced persistent fatigue and reduced physical function.
"Our findings have important implications for patient care. Tests already exist for several of the chronic viruses studied, and some viruses in the herpes family can be treated with existing antiviral drugs," said study principal investigator Melamed, assistant professor of neurology at Dell Medical School.
"The next step is determining whether identifying and treating reactivated viruses can improve outcomes for patients with acute COVID-19 and long COVID."
The study may also influence future treatment strategies. Researchers noted that, instead of targeting only SARS-CoV-2, clinicians may eventually be able to use existing antiviral drugs against reactivated viruses, particularly herpesviruses.
A Phase II clinical trial is already underway to evaluate antiviral therapies targeting herpesviruses in people with long COVID.
Credit: AI
In a landmark decision, the US Food and Drug Administration (FDA) has approved Moderna's first mRNA-based seasonal influenza vaccine.
This makes it the first flu shot developed on messenger RNA (mRNA) technology to receive clearance in the United States.
The vaccine, branded mFlusiva, has been approved for adults over the age of 50 and older, paving the way for a new generation of influenza vaccines beyond the traditional egg-based approach.
The approval has given Moderna commercial drug built on the mRNA platform that powered its COVID-19 vaccine. The development is expected to strengthen the company's efforts to grow its respiratory vaccine portfolio.
According to the FDA, the following groups of people are eligible to receive mFlusiva:
Also read: Ebola Outbreak: Moderna Begins First Human Trial Of Bundibugyo Vaccine As Cases Rise to 3,748
The approval was based on a late-stage clinical trial involving more than 40,000 adults aged 50 years and above. According to trial results, mFlusiva was:
Commenting on the approval, Moderna said, "Flu remains a significant public health challenge, and mFlusiva provides an important new option for America's seniors."
Earlier this year, Moderna CEO Stéphane Bancel had expressed confidence that the vaccine could become available ahead of the 2026-27 flu season if approved by regulators.
Also read: Protective Antibodies Fade After COVID-19 Vaccination- Should You Get A Booster Shot?
Unlike traditional flu vaccines, which are developed using viruses grown in chicken eggs, mRNA vaccines work by transmitting genetic instructions that alert the body's cells to produce harmless influenza proteins for an immune response.
Traditional flu vaccines must be designed and manufactured months before the flu season begins, requiring scientists to predict which influenza strains will circulate. If the circulating viruses keep evolving differently, the effectiveness of the vaccine can decline.
mRNA technology has a major advantage because it can potentially be updated and manufactured much faster, allowing vaccines to better match the strains that are spreading during a particular season.
In February 2026, the FDA initially declined to review Moderna's application, citing concerns that the company had compared its vaccine against a standard-dose flu shot rather than the high-dose vaccine commonly recommended for older adults.
After discussions with regulators, Moderna revised its submission, and the FDA agreed to proceed with the review under a condition that included additional studies for older patients.
Experts say the FDA's decision represents more than the approval of a single vaccine. It marks the first regulatory endorsement of mRNA technology for seasonal influenza, a milestone that could accelerate the development of next-generation vaccines against various infectious diseases.
© 2024 Bennett, Coleman & Company Limited